L’Oréal USA creates salon distribution arm
This article was originally published in The Rose Sheet
Executive Summary
L'Oréal USA acts upon its plan to establish a separate business for distribution of its professional products with creation of SalonCentric. The move consolidates Maly's and Beauty Alliance, purchased in 2007, with Columbia Beauty Supply, a 2008 acquisition for the firm. "SalonCentric is based on a foundation of bringing new proximity and value to hairdressers and better service to salon customers along with the benefits of vertical integration," says David Craggs, president of L'Oréal USA's professional product division. The new operation will be led by Paul Sharnsky, former senior VP & general manager for L'Oréal's professional products division. In a same-day release, Pat Parenty's promotion to brand president, L'Oréal USA Professional Products, is announced. Firm also names Karen Fuss-Zipp VP and general manager, Redken and PureOlogy, while Shae Kalyani is made VP, marketing for those brands
You may also be interested in...
L'Oreal USA acquisition
French cosmetic giant's U.S. business announces acquisition of distributor C.B. Sullivan Company under its SalonCentric professional salon products division. The New Hampshire-based distributor of professional beauty products comprises 31 professional stores, 29 professional sales consultants and a workforce of 270 employees, with net sales of about $50 mil., L'Oreal USA says June 1. "This acquisition is another strategic step in developing a rapidly growing distribution portfolio throughout the U.S.," says Paul Sharnsky, president of SalonCentric. The distributor's "established territories in the Northeast complement our existing coverage in other parts of the country," he adds. L'Oreal USA announced plans to increase its presence in the professional distribution channel three years ago, and last year launched its SalonCentric division to bring new value to hair dressers and better service to salon customers (1"The Rose Sheet" Feb. 16, 2009, In Brief)
L’Oreal ownership
The Bettencourt family and food giant Nestle "will continue on acting in concert toward the L'Oreal company" following expiration of a shareholder pact at the end of the month, the parties stated April 9. On April 29, each party will have the option of selling or increasing its roughly 30% stake in the company, and each has the right of first refusal if the other wants to unload its share. Under the current arrangement, neither the Bettencourts nor Nestle can purchase more shares of the company until six months after the death of 86-year-old Liliane Bettencourt, only child of the L'Oreal founder Eugene Schueller and principal shareholder of L'Oreal SA. Nestle has indicated in recent years that it may consider acquiring L'Oreal, but now reportedly says it is in no hurry to make a decision. Some analysts are saying Nestle would be ill-advised to acquire the cosmetics firm, but speculation no doubt will continue. L'Oreal USA sweeps up Idaho Barber & Beauty: Beauty distributor chain Idaho Barber & Beauty Supply has been acquired by L'Oreal USA, according to an April 9 release. The move is in line with a string of recent purchases by the L'Oreal division designed to strengthen its presence in the professional products distribution market, including Maly's West in 2007 and Columbia Beauty Supply in 2008. IB&B will become part of Maly's West under L'Oreal USA's SalonCentric distribution arm, created earlier this year (1"The Rose Sheet" Feb. 16, 2009, In Brief). IB&B serves over 5,000 salons in Idaho, Montana, Washington and other western states, the firm notes. "This acquisition gives us a stronger presence in the Western part of the country and allows us to combine our expertise in the areas of education, supply chain management, service to salons and, of course, the continuing fight against diversion," says SalonCentric President Paul Sharnsky. Terms of the deal were not disclosed
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.